Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01466322 (ClinicalTrials.gov)	December 22, 2010	3/11/2011	A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.	An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state	GlaxoSmithKline	NULL	Completed	18 Years	55 Years	All	16	Phase 1	Australia
2	NCT01431937 (ClinicalTrials.gov)	October 10, 2010	11/8/2011	Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers	A Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Ascending Doses of GSK2018682 (S1P1 Agonist) in Healthy Volunteers	Multiple Sclerosis, Relapsing-Remitting	Drug: GSK2018682;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	55 Years	All	40	Phase 1	Australia
3	NCT01387217 (ClinicalTrials.gov)	May 21, 2010	14/4/2011	GSK2018682 FTIH in Healthy Volunteers	A Single-blind, Placebo-controlled, Two Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of GSK2018682 in Healthy Volunteers	Multiple Sclerosis	Drug: GSK2018682;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	55 Years	All	27	Phase 1	Australia